Lesson plan

1Z2MAP1O

1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor modulator of the indolizinylethylamine family. It is an analogue of BK-NM-AMT (β-keto-N-methyl-α-methyltryptamine) in which the indole ring has been replaced with an indolizine ring. 1Z2MAP1O has been found to be a serotonin and dopamine releasing agent as well as a weak serotonin 5-HT 1B receptor agonist and serotonin 5-HT 2B receptor antagonist. Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47 screened targets. The drug's values for induction of monoamine release were 109 nM for serotonin and 227 nM for dopamine in Chinese hamster ovary (CHO) cells expressing the human monoamine transporters (MATs). The dopamine/serotonin ratio was 0.48. Its at the serotonin 5-HT 1B receptor was 1,130 nM, whereas its values were 2,140 nM at the serotonin 5-HT 2B receptor, 2,410 nM at the dopamine transporter (DAT), and 5,690 nM at the norepinephrine transporter (NET). 1Z2MAP1O's inhibition of the serotonin transporter (SERT) was not reported. 1Z2MAP1O was patented by Matthew Baggott of Tactogen in 2023.

Back to article

Article summary

1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor modulator of the indolizinylethylamine family. It is an analogue of BK-NM-AMT (β-keto-N-methyl-α-methyltryptamine) in which the indole ring has been replaced with an indolizine ring. 1Z2MAP1O has been found to be a serotonin and dopamine releasing agent as well as a weak serotonin 5-HT 1B receptor agonist and serotonin 5-HT 2B receptor antagonist. Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47 screened targets. The drug's values for induction of monoamine release were 109 nM for serotonin and 227 nM for dopamine in Chinese hamster ovary (CHO) cells expressing the human monoamine transporters (MATs). The dopamine/serotonin ratio was 0.48. Its at the serotonin 5-HT 1B receptor was 1,130 nM, whereas its values were 2,140 nM at the serotonin 5-HT 2B receptor, 2,410 nM at the dopamine transporter (DAT), and 5,690 nM at the norepinephrine transporter (NET). 1Z2MAP1O's inhibition of the serotonin transporter (SERT) was not reported. 1Z2MAP1O was patented by Matthew Baggott of Tactogen in 2023.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.